Based on pivotal trials, it was licensed in Japan for metastatic HER2‐positive breast cancer (BC) in 20013 and for metastatic HER2‐positive gastric cancer (GC) in 2011.4 The gene discussed is ERBB2; the disease is gastric cancer.